To understand the importance of such a screening campaign for preventable chronic diseases with a high incidence, it is necessary to review some figures.
The medical context in Luxembourg
• Cardiovascular diseases (CVD) represent the first cause of death; almost 80% of the country’s population has a preventable cardiovascular risk factor.
• The spectrum of CVD is closely intertwined with that of other chronic pathologies, in particular chronic kidney disease and diabetes.
• 6.5% of the Luxembourg population has diabetes; one third of diabetics are unaware of their condition.
• According to the latest data on chronic kidney disease, 6.3% of people living in the Grand Duchy are affected by it. This risk is 3 to 4 times higher in the case of high blood pressure and diabetes respectively.
Screen, prevent and support
Aware of the importance of preventing these diseases, the medical analysis laboratory Bionext has therefore decided to organise Health Check Week, in collaboration with the biopharmaceutical laboratory Boehringer Ingelheim.
Dr Thibault Labrunie, medical biologist at Bionext, tells us about the organisation: “During Health Check Week, targeted screening at no cost will enable chronic diseases to be detected early. To do this, we’ll be carrying out blood and urine tests to calculate personalised risk scores. On this basis, patients can be referred for appropriate follow-up, if necessary.”
Stéphane Soulard, head of market access & public affairs at Boehringer Ingelheim Belgium and Luxembourg, explains why the biopharmaceutical company is involved in this organisation: “This new screening campaign is an opportunity for us to reaffirm the importance of early detection of cardio-renal-metabolic (C-R-M) diseases. This prevents pathologies from cascading downwards, leading to a reduced quality of life for patients, and significant costs for healthcare systems.”
“The prevention and management of these diseases have become priorities at the European level, with the expected European cardiovascular plan which, I hope, will include concrete and structured actions on the detection and prevention of cardiovascular diseases and their complications,” Stéphane Soulard continues. “Also, this action is fully aligned with the government’s desire to place prevention and early detection on the same level as curative medicine, as described in the coalition agreement.”
The alliance between Bionext and Boehringer Ingelheim therefore has one objective: to prevent in order to act before it is too late.
Health Check Week in practice
• From Monday 1 December to Saturday 6 December.
• Accessible to all, residents and cross-border commuters.
• No appointment, no charge, no prescription required.
• Four risk scores calculated for each patient.
• In eight Bionext laboratories (all week) and the Labomobile—Gare de Luxembourg (on Friday 5 December).
For more information, visit bionext.lu/fr/health-check-week.
A full version of this article is also available in French.
